[0024] Cannabidiolic acid (CBDA) is the main form in which CBD exists in the cannabis plant. It is converted into CBD after decarboxylation.

[0025] Cannabidivarin (CBDV) is a homolog of CBD, with the sidechain shortened by two methylene bridges. CBDV is a non-psychoactive cannabinoid and has been shown to have anti-convulsant activity in a mouse model of epilepsy.

[0026] Cannabidiol-C1 (CBD-C1) also known as cannabidiorcol is a homolog of CBD, with the sidechain shortened by four methylene bridges. CBD-C1 occurs naturally in plants producing CBD but has not been shown to have any therapeutic effects.

[0027] Cannabidiol-C4 (CBD-C4) also known as nor-cannabidiol is a homolog of CBD, with the sidechain shortened by one methylene bridge. CBD-C4 occurs naturally in plants producing CBD and prior to the present invention has not been shown to have any therapeutic effects.

[0028] Cannabidiol-C6 (CBD-C6) is a homolog of CBD, with the sidechain increased by one methylene bridge. CBD-C6 may occur naturally in plants producing CBD and prior to the present invention has not been shown to have any therapeutic effects.

[0029] The present invention demonstrates data for the first time to indicate that the compound 6-hydroxy cannabidivarin may have therapeutic benefit.

BRIEF SUMMARY ~~OF THE DISCLOSURE~~

[0029a] According to a first aspect, the present disclosure refers to a 6-hydroxy cannabidivarin (6-OH CBDV) for use as a medicament.

[0029b] According to another aspect, the present disclosure refers to a composition for use as a medicament comprising 6-hydroxy cannabidivarin (6-OH CBDV) and one or more pharmaceutically acceptable excipients.

[0029c] According to yet another aspect, the present disclosure refers to a use of 6-hydroxy cannabidivarin (6-OH CBDV) in the manufacture of a medicament for the treatment of epilepsy.

[0029d] According to a further aspect, the present disclosure refers to a use of a composition comprising 6-hydroxy cannabidivarin (6-OH CBDV) and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for the treatment of epilepsy.

[0029e] According to another aspect, the present disclosure refers to a process for the preparation of 6-hydroxy cannabidivarin (6-OH CBDV).

[0030] In accordance with a first ~~aspect~~ example of the present ~~invention~~ disclosure there is provided 6-hydroxy cannabidivarin (6-OH CBDV) for use as a medicament.

[0031] Preferably the 6-OH CBDV is present as a synthetic compound. Alternatively, the 6-OH CBDV is present as a pure and isolated compound.

[0032] Preferably the dose of 6-OH CBDV is greater than 100 mg/kg/day. More preferably the dose of 6-OH CBDV is greater than 250 mg/kg/day. More preferably the dose of 6-OH CBDV is greater than 500 mg/kg/day. More preferably the dose of 6-OH CBDV is greater than 750 mg/kg/day. More preferably the dose of 6-OH CBDV is greater than 1000 mg/kg/day. More preferably the dose of 6-OH CBDV is greater than 1500 mg/kg/day.

[0033] Alternatively, the dose of 6-OH CBDV is less than 100 mg/kg/day. More preferably the dose of 6-OH CBDV is less than 50 mg/kg/day. More preferably the dose of 6-OH CBDV is less than 20 mg/kg/day. More preferably the dose of 6-OH CBDV is less than 10 mg/kg/day. More preferably the dose of 6-OH CBDV is less than 5 mg/kg/day. More preferably the dose of 6-OH CBDV is less than 1mg/kg/day. More preferably the dose of 6-OH CBDV is less than 0.5 mg/kg/day.

CLAIMS

1. 6-hydroxy cannabidivarin (6-OH CBDV) for use as a medicament.

2. 6-OH CBDV for use according to claim 1, wherein the 6-OH CBDV is in the form of a synthetic compound.

3. 6-OH CBDV for use according to claim 1, wherein the 6-OH CBDV is in the form of a pure or isolated compound.

4. 6-OH CBDV for use according to any of the preceding claims, wherein the dose of 6-OH CBDV is greater than 100 mg/kg/day.

5. 6-OH CBDV for use according to any of ~~the preceding claims~~claims 1-3, wherein the dose of 6-OH CBDV is less than 100 mg/kg/day.

6. A composition for use as a medicament comprising 6-hydroxy cannabidivarin (6-OH CBDV) and one or more pharmaceutically acceptable excipients.

7. Use of 6-hydroxy cannabidivarin (6-OH CBDV) ~~for use~~ in the manufacture of a medicament for the treatment of epilepsy.

8. ~~6-OH CBDV for~~The use according to claim 7, wherein the epilepsy treated is in a mammal.

9. ~~6-OH CBDV for~~The use according to claim 8, wherein the mammal is a human.

10. ~~6-OH CBDV for~~The use according to claim 8, wherein the mammal is a dog.

11. The use according to any of claims 7-10, wherein the 6-OH CBDV is in the form of a synthetic compound.

12. The use according to any of claims 7-10, wherein the 6-OH CBDV is in the form of a pure or isolated compound.

13. The use according to any of claims 7-12, wherein the dose of 6-OH CBDV is greater than 100 mg/kg/day.

14. The use according to any of claims 7-12, wherein the dose of 6-OH CBDV is less than 100 mg/kg/day.

15. Use of a composition comprising 6-hydroxy cannabidivarin (6-OH CBDV) and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for the treatment of epilepsy.

~~11.~~16. A process for the preparation of 6-hydroxy cannabidivarin (6-OH CBDV).